Market Size of End-stage Renal Disease Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 10.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
End Stage Renal Disease Market Analysis
The end-stage renal disease market is expected to witness a CAGR of around 10% during the forecast period.
The COVID-19 pandemic forced unprecedented changes in the daily life of people. Many patients were under lockdown during this time, and the nephrology community was forced to adapt quickly to this new reality. Patients on dialysis were at high risk of COVID-19 exposure due to the widespread use of public transportation and densely packed clinical spaces. For instance, according to an article published by Karger in June 2022, chronic hemodialysis (HD) patients were considered at high risk of severe COVID-19 with an increased risk of death, and the constraints during the pandemic had an impact on the dialysis delivery to COVID-free hemodialysis patients. Thus the COVID-19 pandemic had a significant effect on the current market initially. However, post-pandemic, the market studied is expected to grow significantly during the forecast period.
The end-stage renal disease market is driven by the increasing number of patients suffering from chronic kidney disease. According to the article published by PubMed Central in April 2022, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. According to the same article, the rate of patients with chronic kidney disease is increasing.
Another factor is the introduction of technologically advanced products, like low-maintenance dialysis equipment and artificial kidney. In March 2021, Baxter International Inc. announced the United States FDA clearance of its next-generation Artificial Kidney 98 dialysis machine, designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. This indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.
Additionally, there is a higher prevalence rate for diabetes, which leads to cause end-stage renal disease in the long run, which may drive the market growth. According to the International Diabetes Federation, in 2021, around 537 million adults (20-79 years) were living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 by 2045. Diabetes is one of the leading causes of kidney failure, which is likely to drive the market's growth over the forecast period.
Therefore, owing to the factors mentioned above, such as the rising prevalence of diabetes and the introduction of technologically advanced products, the market studied is anticipated to witness growth over the analysis period. However, the delay in diagnosing chronic kidney disease may restrain the market growth over the forecast period.
End Stage Renal Disease Industry Segmentation
End-stage renal failure, also known as an end-stage renal disease (ESRD), is the final, permanent stage of chronic kidney disease, where kidneys can no longer function independently.
The End-stage Renal Disease Market is Segmented by Treatment (Kidney Transplantation and Dialysis), Diagnosis (Blood Test, Urine Test, Imaging Test, and Other Diagnoses), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.
| By Treatment | |
| Kidney Transplantation | |
| Dialysis |
| By Diagnosis | |
| Blood Test | |
| Urine Test | |
| Imaging Test | |
| Other Diagnoses |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
End-stage Renal Disease Market Size Summary
The end-stage renal disease market is poised for significant growth, driven by an increasing prevalence of chronic kidney disease and diabetes, which are leading causes of kidney failure. The market is experiencing a transformation due to the introduction of technologically advanced products, such as low-maintenance dialysis equipment and portable artificial kidneys, which are enhancing treatment accessibility and efficiency. The COVID-19 pandemic initially disrupted dialysis services, but the market has since adapted and is expected to expand as the demand for dialysis rises globally. The aging population, lifestyle changes, and improved diagnostic capabilities are further contributing to the market's growth trajectory.
Regionally, Asia-Pacific is anticipated to witness robust market expansion, fueled by high disposable incomes, a broad population base, and a significant acceptance of advanced medical technologies. The region's growing incidence of diabetes and hypertension is also a key factor driving market growth. The market is characterized by fragmentation, with numerous major players employing both organic and inorganic growth strategies, such as product launches, acquisitions, and partnerships, to strengthen their market positions. The presence of a large number of dialysis centers, particularly in India, and increasing patient affordability are expected to further boost market development in the coming years.
End-stage Renal Disease Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increase in Number of Patient Suffering from Chronic Kidney Disease
-
1.2.2 Introduction of Technologically Advanced Products
-
1.2.3 Rising Prevalence of Diabetes and Hypertension
-
-
1.3 Market Restraints
-
1.3.1 Delay in Diagnosis of the Chronic Kidney Disease
-
-
1.4 Industry Attractiveness - Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Buyers/Consumers
-
1.4.2 Bargaining Power of Suppliers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value in USD million)
-
2.1 By Treatment
-
2.1.1 Kidney Transplantation
-
2.1.2 Dialysis
-
-
2.2 By Diagnosis
-
2.2.1 Blood Test
-
2.2.2 Urine Test
-
2.2.3 Imaging Test
-
2.2.4 Other Diagnoses
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
End-stage Renal Disease Market Size FAQs
What is the current End-stage Renal Disease Market size?
The End-stage Renal Disease Market is projected to register a CAGR of 10% during the forecast period (2024-2029)
Who are the key players in End-stage Renal Disease Market?
Nipro Corporation , Fresenius SE & Co. KGaA, Baxter International Inc, Medtronic PLC and B. Braun SE are the major companies operating in the End-stage Renal Disease Market.
